{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:28:05Z","timestamp":1790810885340,"version":"4.1.0"},"reference-count":41,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2019,7,16]],"date-time":"2019-07-16T00:00:00Z","timestamp":1563235200000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Shionogi & Co., Ltd"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Single-dose baloxavir rapidly reduces influenza virus titers and symptoms in patients with uncomplicated influenza, but viruses with reduced in vitro susceptibility due to amino acid substitutions at position 38 of polymerase acidic protein (PA\/I38X) sometimes emerge.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We evaluated the kinetics, risk factors, and effects on clinical and virologic outcomes of emergence of PA\/I38X-substituted viruses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Viruses containing PA\/I38X substitutions were identified 3\u20139 days after baloxavir treatment in 9.7% (36\/370) of patients, of whom 85.3% had transient virus titer rises. Median time to sustained cessation of infectious virus detection was 192, 48, and 96 hours in the baloxavir recipients with PA\/I38X-substituted viruses, without PA\/I38X-substituted viruses, and placebo recipients, respectively. The corresponding median times to alleviation of symptoms were 63.1, 51.0, and 80.2 hours, respectively. After day 5, symptom increases occurred in 11.5%, 8.0%, and 13.0%, respectively, and in 8.9% of oseltamivir recipients. Variant virus emergence was associated with lower baseline neutralizing antibody titers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The emergence of viruses with PA\/I38X substitutions following baloxavir treatment was associated with transient rises in infectious virus titers, prolongation of virus detectability, initial delay in symptom alleviation, and uncommonly with symptom rebound. The potential transmissibility of PA\/I38X-substituted viruses requires careful study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trial Registration<\/jats:title>\n                    <jats:p>NCT02954354.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/infdis\/jiz244","type":"journal-article","created":{"date-parts":[[2019,5,9]],"date-time":"2019-05-09T07:08:50Z","timestamp":1557385730000},"source":"Crossref","is-referenced-by-count":69,"title":["Treatment-Emergent Influenza Variant Viruses With Reduced Baloxavir Susceptibility: Impact on Clinical and Virologic Outcomes in Uncomplicated Influenza"],"prefix":"10.1093","author":[{"given":"Takeki","family":"Uehara","sequence":"first","affiliation":[{"name":"Shionogi & Co., Ltd, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick G","family":"Hayden","sequence":"additional","affiliation":[{"name":"University of Virginia School of Medicine, Charlottesville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Kawaguchi","sequence":"additional","affiliation":[{"name":"Shionogi & Co., Ltd, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Omoto","sequence":"additional","affiliation":[{"name":"Shionogi & Co., Ltd, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aeron C","family":"Hurt","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menno D","family":"De Jong","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, Academic Medical Center, University of Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuo","family":"Hirotsu","sequence":"additional","affiliation":[{"name":"Hirotsu Clinic, Kawasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Sugaya","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Keiyu Hospital, Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Baba","sequence":"additional","affiliation":[{"name":"Shionogi & Co., Ltd, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Shishido","sequence":"additional","affiliation":[{"name":"Shionogi & Co., Ltd, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Tsuchiya","sequence":"additional","affiliation":[{"name":"Shionogi & Co., Ltd, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Portsmouth","sequence":"additional","affiliation":[{"name":"Shionogi Inc., Florham Park, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kida","sequence":"additional","affiliation":[{"name":"Research Center for Zoonosis Control, Hokkaido University, Sapporo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,7,16]]},"reference":[{"key":"2019071606355876900_CIT0001","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1261\/rna.045369.114","article-title":"Comparative mutational analyses of influenza A viruses","volume":"21","author":"Cheung","year":"2015","journal-title":"RNA"},{"key":"2019071606355876900_CIT0002","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1146\/annurev.micro.51.1.151","article-title":"RNA virus mutations and fitness for survival","volume":"51","author":"Domingo","year":"1997","journal-title":"Annu Rev Microbiol"},{"key":"2019071606355876900_CIT0003","doi-asserted-by":"crossref","first-page":"13910","DOI":"10.1073\/pnas.96.24.13910","article-title":"Mutation rates among RNA viruses","volume":"96","author":"Drake","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2019071606355876900_CIT0004","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1146\/annurev.mi.41.100187.002205","article-title":"Rapid evolution of RNA viruses","volume":"41","author":"Steinhauer","year":"1987","journal-title":"Annu Rev Microbiol"},{"key":"2019071606355876900_CIT0005","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1001\/jama.295.8.joc60020","article-title":"Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States","volume":"295","author":"Bright","year":"2006","journal-title":"JAMA"},{"key":"2019071606355876900_CIT0006","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2147\/IDR.S105473","article-title":"Drug resistance in influenza A virus: the epidemiology and management","volume":"10","author":"Hussain","year":"2017","journal-title":"Infect Drug Resist"},{"key":"2019071606355876900_CIT0007","author":"Centers for Disease Control and Prevention"},{"key":"2019071606355876900_CIT0008","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1056\/NEJMra050740","article-title":"Neuraminidase inhibitors for influenza","volume":"353","author":"Moscona","year":"2005","journal-title":"N Engl J Med"},{"key":"2019071606355876900_CIT0009","doi-asserted-by":"crossref","first-page":"ofx105","DOI":"10.1093\/ofid\/ofx105","article-title":"A review of clinical influenza A and B infections with reduced susceptibility to both oseltamivir and zanamivir","volume":"4","author":"Abed","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"2019071606355876900_CIT0010","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.antiviral.2017.08.004","article-title":"Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2015\u20132016","volume":"146","author":"Gubareva","year":"2017","journal-title":"Antivir Res"},{"key":"2019071606355876900_CIT0011","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1177\/135965350400900404","article-title":"A reverse genetics study of resistance to neuraminidase inhibitors in an influenza A\/H1N1 virus","volume":"9","author":"Abed","year":"2004","journal-title":"Antivir Ther"},{"key":"2019071606355876900_CIT0012","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1086\/424572","article-title":"Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets","volume":"190","author":"Herlocher","year":"2004","journal-title":"J Infect Dis"},{"key":"2019071606355876900_CIT0013","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0166-3542(02)00053-0","article-title":"The H274Y mutation in the influenza A\/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo","volume":"55","author":"Ives","year":"2002","journal-title":"Antiviral Res"},{"key":"2019071606355876900_CIT0014","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1743-422X-6-54","article-title":"Sales of oseltamivir in Norway prior to the emergence of oseltamivir resistant influenza A(H1N1) viruses in 2007-08","volume":"6","author":"Hauge","year":"2009","journal-title":"Virol J"},{"key":"2019071606355876900_CIT0015","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3201\/eid1502.081031","article-title":"Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007-08","volume":"15","author":"Hauge","year":"2009","journal-title":"Emerg Infect Dis"},{"key":"2019071606355876900_CIT0016","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1126\/science.1187816","article-title":"Permissive secondary mutations enable the evolution of influenza oseltamivir resistance","volume":"328","author":"Bloom","year":"2010","journal-title":"Science"},{"key":"2019071606355876900_CIT0017","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1093\/infdis\/jis337","article-title":"Characteristics of a widespread community cluster of H275Y oseltamivir-resistant A(H1N1)pdm09 influenza in Australia","volume":"206","author":"Hurt","year":"2012","journal-title":"J Infect Dis"},{"key":"2019071606355876900_CIT0018","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1128\/AAC.04836-14","article-title":"Characterization of a large cluster of influenza A(H1N1)pdm09 viruses cross-resistant to oseltamivir and peramivir during the 2013\u20132014 influenza season in Japan","volume":"59","author":"Takashita","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071606355876900_CIT0019","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.antiviral.2018.07.001","article-title":"Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors and status of novel antivirals, 2016\u20132017","volume":"157","author":"Lackenby","year":"2018","journal-title":"Antivir Res"},{"key":"2019071606355876900_CIT0020","volume-title":"Global influenza strategy 2019\u20132030","author":"World Health Organization"},{"key":"2019071606355876900_CIT0021","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s40265-018-0899-1","article-title":"Baloxavir: first global approval","volume":"78","author":"Heo","year":"2018","journal-title":"Drugs"},{"key":"2019071606355876900_CIT0022","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJMoa1716197","article-title":"Baloxavir marboxil for uncomplicated influenza in adults and adolescents","volume":"379","author":"Hayden","year":"2018","journal-title":"N Engl J Med"},{"key":"2019071606355876900_CIT0023","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.antiviral.2019.01.012","article-title":"Baloxavir marboxil in Japanese patients with seasonal influenza: dose response and virus type\/subtype outcomes from a randomized phase 2 study","volume":"163","author":"Watanabe","year":"2019","journal-title":"Antiviral Res"},{"key":"2019071606355876900_CIT0024","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.antiviral.2018.10.008","article-title":"In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit","volume":"160","author":"Noshi","year":"2018","journal-title":"Antiviral Res"},{"key":"2019071606355876900_CIT0025","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/nature07745","article-title":"The cap-snatching endonuclease of influenza virus polymerase resides in the PA subunit","volume":"458","author":"Dias","year":"2009","journal-title":"Nature"},{"key":"2019071606355876900_CIT0026","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/med.21401","article-title":"The influenza virus polymerase complex: an update on its structure, functions, and significance for antiviral drug design","volume":"36","author":"Stevaert","year":"2016","journal-title":"Med Res Rev"},{"key":"2019071606355876900_CIT0027","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/nature07720","article-title":"Crystal structure of an avian influenza polymerase PA(N) reveals an endonuclease active site","volume":"458","author":"Yuan","year":"2009","journal-title":"Nature"},{"key":"2019071606355876900_CIT0028","doi-asserted-by":"crossref","first-page":"e00430-18","DOI":"10.1128\/mBio.00430-18","article-title":"Identification of the I38T PA substitution as a resistance marker for next-generation influenza virus endonuclease inhibitors","volume":"9","author":"Jones","year":"2018","journal-title":"mBio"},{"key":"2019071606355876900_CIT0029","doi-asserted-by":"crossref","first-page":"9633","DOI":"10.1038\/s41598-018-27890-4","article-title":"Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil","volume":"8","author":"Omoto","year":"2018","journal-title":"Sci Rep"},{"key":"2019071606355876900_CIT0030","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1002\/jps.2600711209","article-title":"Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods","volume":"71","author":"Sheiner","year":"1982","journal-title":"J Pharm Sci"},{"key":"2019071606355876900_CIT0031","volume-title":"NONMEM users guide: introduction to NONMEM 7.3.0","author":"Bauer","year":"2013"},{"key":"2019071606355876900_CIT0032","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/irv.12534","article-title":"Five years of monitoring for the emergence of oseltamivir resistance in patients with influenza A infections in the Influenza Resistance Information Study","volume":"12","author":"Lina","year":"2018","journal-title":"Influenza Other Respir Viruses"},{"key":"2019071606355876900_CIT0033","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1093\/cid\/cis1220","article-title":"Global assessment of resistance to neuraminidase inhibitors, 2008\u20132011: the Influenza Resistance Information Study (IRIS)","volume":"56","author":"Whitley","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2019071606355876900_CIT0034","doi-asserted-by":"crossref","first-page":"10524","DOI":"10.1128\/JVI.00832-13","article-title":"Mutational analysis of the binding pockets of the diketo acid inhibitor L-742,001 in the influenza virus PA endonuclease","volume":"87","author":"Stevaert","year":"2013","journal-title":"J Virol"},{"key":"2019071606355876900_CIT0035","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1128\/AAC.35.9.1741","article-title":"Recovery of drug-resistant influenza A virus during therapeutic use of rimantadine","volume":"35","author":"Hayden","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071606355876900_CIT0036","doi-asserted-by":"crossref","first-page":"e0119115","DOI":"10.1371\/journal.pone.0119115","article-title":"Adamantane-resistant influenza A viruses in the world (1902\u20132013): frequency and distribution of M2 gene mutations","volume":"10","author":"Dong","year":"2015","journal-title":"PLoS One"},{"key":"2019071606355876900_CIT0037","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/irv.12176","article-title":"Detection and management of antiviral resistance for influenza viruses","volume":"7","author":"Boivin","year":"2013","journal-title":"Influenza Other Respir Viruses"},{"key":"2019071606355876900_CIT0038","doi-asserted-by":"crossref","first-page":"4929","DOI":"10.3390\/v7092850","article-title":"Clinical implications of antiviral resistance in influenza","volume":"7","author":"Li","year":"2015","journal-title":"Viruses"},{"key":"2019071606355876900_CIT0039","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1073\/pnas.90.9.4171","article-title":"Rates of spontaneous mutation among RNA viruses","volume":"90","author":"Drake","year":"1993","journal-title":"Proc Natl Acad Sci USA"},{"key":"2019071606355876900_CIT0040","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1016\/j.xphs.2018.12.005","article-title":"Population pharmacokinetic and exposure-response analyses of baloxavir marboxil in adults and adolescents including influenza patients","volume":"108","author":"Koshimichi","year":"2019","journal-title":"J Pharm Sci"},{"key":"2019071606355876900_CIT0041","volume-title":"Review Report on Xofluza 10 mg and 20 mg","author":"Pharmaceuticals","year":"2018"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiz244\/28938252\/jiz244.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"}],"deposited":{"date-parts":[[2022,9,17]],"date-time":"2022-09-17T14:27:12Z","timestamp":1663424832000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/advance-article\/doi\/10.1093\/infdis\/jiz244\/5532607"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,16]]},"references-count":41,"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiz244","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,16]]},"article-number":"jiz244"}}